# Panacea Innovation

> Panacea Innovation is a VC fund backing Biotechnology and Health Care. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Oxford, United Kingdom
- Total investments: 9
- Last investment: Sep 2025
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/panacea-innovation/
- X (Twitter): https://twitter.com/PanaceaInnov
- Website: http://panacea-innovation.com
- Facebook: https://www.facebook.com/PanaceaInnovation/

Panacea Innovation is a VC fund in Oxford focused on Biotechnology and Health Care. Panacea Innovation's mission is to change the way the world does science for the betterment of humanity by establishing vehicles that aim to maximize deep science translation and commercialization. The company has two arms—a technology translation, commercialization, and R&D arm and an investment management arm.

## Contacts

5 contacts available for Panacea Innovation. Shizune tracks 1 team members at Panacea Innovation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/panacea-innovation?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 89% |
| Health Care | 3 | 33% |
| Artificial Intelligence | 3 | 33% |
| Biopharma | 2 | 22% |
| Life Science | 2 | 22% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 56% |
| Pre-Seed | 2 | 22% |
| Venture - Series Unknown | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 7 | 78% |
| United States | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Mina Elisha Bekheet | Founder, CEO and Managing Director | 8 | https://shizune.co/investors/profile/mina-elisha-bekheet |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Convexia | Convexia develops AI agents that evaluate drug assets through simulations, clinical profiling, safety prediction, and market analysis. | $500K | Pre-Seed | Sep 09, 2025 |  |
| OutSee | OutSee creates cutting-edge computational methods for genomics for the development of therapeutic targets and precision medicine. | $3.4M | Seed | Jun 24, 2025 |  |
| OutSee | OutSee creates cutting-edge computational methods for genomics for the development of therapeutic targets and precision medicine. | $3.4M | Seed | Jun 24, 2025 |  |
| Ignota Labs | Ignota Labs recognizes that safety errors during the drug discovery process can result in expensive setbacks and delays in bringing life-changing medications to market. Ignota Labs world leading AI methods, which include deep learning and machine learning approaches, are intended to examine complicated molecular data and provide accurate toxicitypredictions. | $6.9M | Seed | Feb 26, 2025 |  |
| Axiom Therapeutics | Axiom Therapeutics is a health tech company that provides computational drug discovery solutions for untreatable cancers. |  | Pre-Seed | Jan 14, 2025 |  |
| MitoRx Therapeutics | MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction. |  | Seed | Nov 01, 2024 |  |
| CardiaTec Biosciences | CardiaTec is a TechBio business that uses computational tools to unravel the biology underlying cardiovascular illness. CardiaTec uses massive and high-dimensional human omics data to better understand complicated disease biology and identify novel and differentiated therapies. | $6.5M | Seed | Sep 10, 2024 |  |
| Oxford Cancer Biomarkers | Oxford Cancer Biomarkers is developing and commercializing a suite of colorectal cancer biomarker tests to improve the current treatment pathway. Oxford Cancer Biomarkers is closely affiliated with Institute of Cancer Medicine at Oxford University, where its founders lead translational cancer science research groups. Oxford Cancer Biomarkers hasalso partnered with pharmaceutical companies to use its discovery platforms CancerNav® and ToxNavTM to develop companion diagnostic tests for pipeline drugs. |  | Venture - Series Unknown | Apr 03, 2023 |  |
| Hutano Diagnostics | Hutano Diagnostic uses aptamer-based recognition elements in its lateral flow diagnostic system, allowing the platform to identify antigens and nucleic acids within a single test format. Its technology supports multiplex detection, enabling users to assess multiple biomarkers simultaneously and tailor each test to specific diagnostic needs. Theplatform's configurable nature enables it to be adapted for various use cases, ranging from clinical screening to specialized testing scenarios. |  | Seed | Sep 15, 2020 |  |

9 of 9 investments shown.

## Co-investors
- [Ahren Innovation Capital](https://shizune.co/investors/profile/ahren-innovation-capital) — VC Fund, 2 deals together
- [Empirical Ventures](https://shizune.co/investors/profile/empirical-ventures) — VC Fund, 2 deals together
- [Kadmos Capital](https://shizune.co/investors/profile/kadmos-capital-43dd) — VC Fund, 2 deals together
- [Montage Ventures](https://shizune.co/investors/profile/montage-ventures) — VC Fund, 2 deals together
- [AIX Ventures](https://shizune.co/investors/profile/aix-ventures) — VC Fund, 1 deal together
- [APEX Ventures](https://shizune.co/investors/profile/apex-ventures-12df) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Panacea Innovation invest in?

Panacea Innovation invests primarily in Biotechnology, Health Care and Artificial Intelligence startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Panacea Innovation?

Public channels for Panacea Innovation include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Panacea Innovation?

The team at Panacea Innovation includes Mina Elisha Bekheet (Founder, CEO and Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co